Can Ventaris Surgical’s $30m-backed system solve the biggest gap in kidney stone treatment?
Ventaris Surgical raises $30M to advance its kidney stone treatment system. Find out how it could reshape ureteroscopy outcomes in 2026.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why the Nanodropper–Bedo–Viseon merger could reset the rules of personalized eyecare
Mu Medical unites Nanodropper, Bedo, and Viseon into a precision eyecare platform. Find out what this could mean for the future of AI-led ophthalmology.
Pharma & Biotech
Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.
Medical Devices & Diagnostics
Why Princeton Radiology is betting on whole-body MRI and breast screening growth
Princeton Radiology acquires two centers from RAI—see how this move reshapes outpatient imaging strategy, tech, and patient services in New Jersey.
Medical Devices & Diagnostics
Labcorp and Quest partner with Visby to expand access to rapid at-home PCR STI test
Visby’s at-home PCR STI test now on Quest and Labcorp. Find out how this redefines women’s health diagnostics and access. Read the full analysis.
Medical Devices & Diagnostics
Can MRI body scans redefine preventive care? AMRA expands into Dutch market with Prescan
AMRA and Prescan launch a first-in-Netherlands MRI scan to assess fat and muscle composition. Learn how this could redefine early disease detection in Europe.
Medical Devices & Diagnostics
Welldoc seeks FDA nod for AI-based glucose prediction in non-insulin type 2 diabetes
Welldoc’s CGM-based glucose prediction tool for non-insulin users is now under FDA review. Find out what it could change in diabetes care.
Pharma & Biotech
Aktis Oncology raises $318m IPO: What this means for alpha radiotherapy biotech bets
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.
Pharma & Biotech
Can functional logic beat genetic drift? MindWalk’s bet on influenza physics
MindWalk says flu can’t mutate past this. Find out how its HYFT AI platform found a functional constraint that may redefine universal vaccine design.
Pharma & Biotech
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.